Low HDL-cholesterol: a strong predictor of glycemic response to glitazone treatment in patients with type 2 diabetes.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Diabetes Research and Clinical Practice

• Publication date

  2011-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.diabres.2011.04.005PMID 21529978
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• patient-oriented and epidemiological research Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes

  2009cited by this paper
• Relationship of baseline HbA1c and efficacy of current glucose‐lowering therapies: a meta‐analysis of randomized clinical trials

  2009cited by this paper
• Indicators for the Efficacy of Pioglitazone Before and During Treatment in Japanese Patients with Type 2 Diabetes

  2007cited by this paper
• Effects of glitazones in the treatment of diabetes and/or hyperlipidaemia: glycaemic control and plasma lipid levels

  2007cited by this paper
• Effect of pioglitazone on atherogenic outcomes in type 2 diabetic patients: a comparison of responders and non-responders.

  2007cited by this paper
• Insulin resistance index as a predictor for pioglitazone treatment in type 2 diabetes.

  2005cited by this paper
• Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus.

  2005cited by this paper
• Comparison of pioglitazone and metformin efficacy using homeostasis model assessment

  2004cited by this paper
• One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.

  2004cited by this paper
• Progress with thiazolidinediones in the management of type 2 diabetes mellitus.

  2004cited by this paper
• Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes.

  2004cited by this paper
• Insulin-Sensitizing Agents –Thiazolidinediones (Glitazones)

  2002cited by this paper
• The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.

  2002cited by this paper
• A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.

  2001cited by this paper
• Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

  2000cited by this paper
• Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

  2000cited by this paper
• The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes

  1999cited by this paper
• Evidence for an independent relationship between insulin resistance and fasting plasma HDL‐cholesterol, triglyceride and insulin concentrations

  1992cited by this paper

• No improvement of high-density lipoprotein (HDL) vasorelaxant effect despite increase in HDL cholesterol concentration in type 2 diabetic patients treated with glitazones.

  2014cites this paper
• Thiazolidinediones and PPARγ agonists: time for a reassessment.

  2012cites this paper
• Current world literature.

  2006cites this paper